v3.25.1
SCHEDULE OF RESTATEMENT CONSOLIDATED FINANCIAL STATEMENTS (Details) - USD ($)
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Current Assets:      
Cash  
Total Current Assets 45,842 81,223  
TOTAL ASSETS 6,714,364 19,982,392  
Current Liabilities:      
Accounts Payable 1,030,615 152,005  
Other Current Liabilities 358,939 238,939  
Total Current Liabilities 15,616,047 403,328  
TOTAL LIABILITIES 15,616,047 403,328  
Stockholders Equity:      
Additional paid-in-capital 8,802,978 10,964,930  
Accumulated Deficit (24,373,902) (11,287,754)  
Total shareholders’ deficit (15,570,205) (322,105) $ (9,937,901)
TOTAL LIABILITIES, REDEEMABLE ORDINARY SHARES AND SHAREHOLDERS’ DEFICIT 6,714,364 19,982,392  
Aspire Biopharma Inc [Member]      
Current Assets:      
Cash 3,633 11,174  
Prepaid Expenses 144,356 35,000  
Total Current Assets 147,989 46,174  
TOTAL ASSETS 147,989 46,174  
Current Liabilities:      
Accounts Payable 310,219 172,773  
Short-term loans from shareholders 1,266,832 360,636  
Other Current Liabilities 111,026 626  
Total Current Liabilities 1,688,077 534,035  
TOTAL LIABILITIES 1,688,077 534,035  
Stockholders Equity:      
Common stock - Par Value $0.001 $ 22,000 $ 22,000  
Common stock par value $ 0.00005 $ 0.00005  
Additional paid-in-capital $ 1,215,113 $ 957,500  
Accumulated Deficit (2,777,233) (1,467,361)  
Total shareholders’ deficit (1,540,088) (487,861)  
TOTAL LIABILITIES, REDEEMABLE ORDINARY SHARES AND SHAREHOLDERS’ DEFICIT $ 147,989 46,174  
Previously Reported [Member] | Aspire Biopharma Inc [Member]      
Current Assets:      
Cash   11,174  
Prepaid Expenses   35,000  
Total Current Assets   46,174  
TOTAL ASSETS   46,174  
Current Liabilities:      
Accounts Payable   172,773  
Short-term loans from shareholders   360,636  
Other Current Liabilities   626  
Total Current Liabilities   534,035  
TOTAL LIABILITIES   534,035  
Stockholders Equity:      
Common stock - Par Value $0.001   221,500  
Common stock par value $ 0.01    
Additional paid-in-capital   758,000  
Accumulated Deficit   (1,467,361)  
Total shareholders’ deficit   (487,861)  
TOTAL LIABILITIES, REDEEMABLE ORDINARY SHARES AND SHAREHOLDERS’ DEFICIT   46,174  
Revision of Prior Period, Adjustment [Member] | Aspire Biopharma Inc [Member]      
Current Assets:      
Cash   11,174  
Prepaid Expenses   35,000  
Total Current Assets   46,174  
TOTAL ASSETS   46,174  
Current Liabilities:      
Accounts Payable   172,773  
Short-term loans from shareholders   360,636  
Other Current Liabilities   626  
Total Current Liabilities   534,035  
TOTAL LIABILITIES   534,035  
Stockholders Equity:      
Common stock - Par Value $0.001   $ 22,000  
Common stock par value   $ 0.001  
Additional paid-in-capital   $ 957,500  
Accumulated Deficit   (1,467,361)  
Total shareholders’ deficit   (487,861)  
TOTAL LIABILITIES, REDEEMABLE ORDINARY SHARES AND SHAREHOLDERS’ DEFICIT   46,174  
Revision of Prior Period, Reclassification, Adjustment [Member] | Aspire Biopharma Inc [Member]      
Current Assets:      
Cash    
Prepaid Expenses    
Total Current Assets    
TOTAL ASSETS    
Current Liabilities:      
Accounts Payable    
Short-term loans from shareholders    
Other Current Liabilities    
Total Current Liabilities    
TOTAL LIABILITIES    
Stockholders Equity:      
Common stock - Par Value $0.001   (199,500)  
Additional paid-in-capital   199,500  
Accumulated Deficit    
Total shareholders’ deficit    
TOTAL LIABILITIES, REDEEMABLE ORDINARY SHARES AND SHAREHOLDERS’ DEFICIT